BSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,174.30
- Market cap
- ₹1,18,162 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.2×Sector 46.1×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Partnership
Zydus Lifesciences' division Zylidac Bio partnered with Prolific Machines to scale their next-generation biologics manufacturing platform for GMP production.
Zydus Lifesciences Regulatory Approval
Zydus Lifesciences received USFDA approval for its Estradiol-Levonorgestrel Transdermal System ANDA, designated as a CGT. The product is eligible for 180-day exclusivity upon first commercial marketing.
Zydus Lifesciences Board Meeting Date
Zydus Lifesciences intimated a board meeting on 4 Nov 2026 to approve unaudited Q1/H1 FY27 results. Trading window remains closed until 6 Nov 2026.
Zydus Lifesciences Other Announcement
Zydus Lifesciences Limited has been assigned an ESG rating of 71 by NSRAL for the financial year 2026. This unsolicited rating reflects the company's sustainability performance.
Zydus Lifesciences Capacity Expansion: ₹190 Cr Investment
Zydus' JV with Sunshine Healthcare signed a BOI agreement to establish a pharma plant in Sri Lanka. Investment exceeds USD 20 million (~₹190 Cr), targeting 2028.
- Value
- ₹190.0 Cr
Zydus Lifesciences Business Update
Zydus Lifesciences presented post-hoc analysis from its EPICS-III clinical trial for Saroglitazar at ACG 2026. The drug remains under regulatory review for PBC treatment.
Other board meeting date announcements
All →Valiant Communications Board Meeting Date
Valiant Communications intimated that its Board will meet on 05-11-2026, inter alia to consider the Q1 FY27 unaudited results. The trading window stays closed until 48 hours after the results are announced.
Hannah Joseph Hospital Board Meeting Date
Hannah Joseph Hospital Ltd intimated a Board meeting on 05/11/2026 to approve H1 FY27 unaudited results. The trading window has been closed pending that announcement.
Kinetic Trust Board Meeting Date
Kinetic Trust Ltd intimated a Board meeting on 04/11/2026. The agenda includes approval of quarterly financial statements.
Lake Shore Realty Board Meeting Date
Lake Shore Realty Ltd has scheduled a board meeting on 02 Nov 2026 to approve unaudited standalone financial results for Q2 H1 FY27. No other agenda items specified beyond routine matters.
GTV Engineering Board Meeting Date
GTV Engineering scheduled a Board Meeting for 5 November 2026 to approve unaudited Q2 and half-year financial results. No new information is disclosed beyond the meeting notice.
Elixir Capital Board Meeting Date
Elixir Capital Ltd notified BSE that its Board will meet on 6 Nov 2026 to consider Q2/H1FY27 results. No financial figures or decisions are reported yet.